Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
18.07
-0.39 (-2.11%)
Aug 6, 2026, 4:00 PM EDT - Market closed

Amneal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $20.75. The average 1-year stock price forecast is 14.83% higher than the current stock price, while the lowest is $16 (-11.46%) and the highest is $25 (+38.35%).

Price Target: $20.75 (+14.83%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$16$20.75$21$25
Change-11.46%+14.83%+16.21%+38.35%

Analyst Ratings

The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy233222
Buy322222
Hold000000
Sell000000
Strong Sell000000
Total555444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Maintains
$23$25
BuyMaintains$23$25+38.35%Aug 3, 2026
Goldman Sachs
Goldman Sachs
Buy
Reiterates
$19$21
BuyReiterates$19$21+16.21%Jul 31, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$17
BuyReiterates$17-5.92%Jul 20, 2026
Barclays
Barclays
Buy
Maintains
$16
BuyMaintains$16-11.46%Jun 11, 2026
Truist Financial
Truist Financial
Buy
Maintains
n/a
BuyMaintainsn/an/aApr 23, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.14B
from 3.02B
Increased by 4.13%
Revenue Next Year
3.39B
from 3.14B
Increased by 7.77%
EPS This Year
1.01
from 0.83
Increased by 21.11%
EPS Next Year
1.18
from 1.01
Increased by 17.65%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
2.09B2.21B2.39B2.79B3.02B3.14B
Revenue Growth
5.08%5.67%8.20%16.73%8.05%4.13%
Gross Profit
783.95M791.46M852.87M1.02B1.13B1.41B
Gross Margin
37.44%35.78%35.63%36.35%37.38%45.00%
Operating Income
216.60M200.03M260.38M348.36M420.70M713.07M
Net Income
10.62M-129.99M-83.99M-116.89M72.06M148.81M
EPS
----0.831.01
EPS Growth
----43.10%21.11%
Forward PE
5.652.7111.9211.6915.0417.98
Free Cash Flow
217.65M120.14M300.39M253.45M197.07M200.39M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High3.2B
Avg3.1B
Low3.1B

Revenue Growth

Revenue Growth202620272028
High
5.3%
Avg
4.1%
Low
3.2%

EPS Forecast

EPS202620272028
High1.03
Avg1.01
Low0.94

EPS Growth

EPS Growth202620272028
High
24.1%
Avg
21.1%
Low
13.1%